Healthcare Market Updates | BioTuesdays by Kilmer Lucas IR

Markets

Janney starts Applied Genetic Technologies at buy; fair value estimate $13

Janney initiated coverage of Applied Genetic Technologies (NASDAQ:AGTC) with a “buy” rating and fair value estimate of $13. The stock closed at $3.20 on Sept. 5. “We see a highly attractive investment opportunity in...

September 6, 2019

Markets

Stereotaxis to uplist to NYSE American

The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on...

September 5, 2019

Markets

HCW cuts Tetraphase Pharma to neutral and removes PT

H.C. Wainwright downgraded Tetraphase Pharmaceuticals (NASDAQ:TTPH) to “neutral” from “buy” and removed its price target, citing an early debt payoff that substantially increases the company’s risk. The stock closed at...

September 3, 2019

Markets

AGP starts coverage of Itamar Medical at buy; PT $15.50

Alliance Global Partners initiated coverage of Itamar Medical (NASDAQ:ITMR) with a “buy” rating and $15.50 price target. The stock closed at $9.10 on Aug. 29. “We see Itamar as the technology leader in home sleep...

August 30, 2019

Markets

Stifel ups Tabula Rasa HealthCare to buy; PT to $75 from $70

Stifel upgraded Tabula Rasa HealthCare (NASDAQ:TRHC) to “buy” from “hold” and raised its price target to $75 from $70, citing an “improving risk/reward with a favorable fundamental backdrop.” The stock closed at $57.64...

August 30, 2019

Markets

HCW starts TRACON Pharma at buy; PT $2

H.C. Wainwright launched coverage of TRACON Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $2 price target. The stock closed at 57 cents on Aug. 29. TRACON is developing targeted therapeutics for cancer...

August 30, 2019

Markets

WB starts VistaGen Therapeutics at OP; fair value estimate $7

William Blair launched coverage of VistaGen Therapeutics (NASDAQ:VTGN) with an “outperform” rating and fair value estimate of $7. The stock closed at 60 cents on Aug. 27. VistaGen Therapeutics is focused on developing...

August 28, 2019

Markets

Stifel starts Cerus at buy; PT $7

Stifel initiated coverage of Cerus (NASDAQ:CERS) with a “buy” rating and $7 price target. The stock closed at $5.21 on Aug. 27. “Over time, we see significant potential upside as the company executes against its high...

August 28, 2019

Markets

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...

August 26, 2019

Markets

Dawson James starts Fortress Biotech at buy; PT $19

Dawson James Securities launched coverage of Fortress Biotech (NASDAQ:FBIO) with a “buy” rating and price target of $19. The stock closed at $6.51 on Aug. 23. “Creating a launch pad for biotechnology assets, Fortress...

August 26, 2019

Markets

HCW starts Sangamo Therapeutics at buy; PT $16

H.C. Wainwright initiated coverage of Sangamo Therapeutics (NASDAQ:SGMO) with a “buy” rating and $16 price target. The stock closed at $11.02 on Aug. 23. Analyst Debjit Chattopadhyay writes that the prevailing view on...

August 26, 2019

Markets

Dawson James starts Athersys at buy; PT $11

Dawson James Securities launched coverage of Athersys (NASDAQ:ATHX) with a “buy” rating and $11 price target. The stock closed at $1.40 on Aug. 23. “Athersys has the potential to change the treatment paradigm for...

August 26, 2019

Markets

HCW starts INmune Bio at buy; PT $11.50

H.C. Wainwright launched coverage of INmune Bio with a “buy” rating and price target of $11.50. The stock closed at $5.94 on Aug. 20. INmune Bio is an immunology company developing therapies targeting innate immunity to...

August 21, 2019

Markets

HCW starts Targovax ASA at buy; PT 19 NOK

H.C. Wainwright initiated coverage of Oslo-based Targovax ASA (OSE:TRVX) with a “buy” rating and price target of 19 NOK. The stock closed at 5.44 NOK on Aug. 19. Analyst Joseph Pantginis writes that Targovax’s lead...

August 20, 2019

Markets

BTIG cuts Synlogic PT to $9 from $22

BTIG reduced its price target for Synlogic (NASDAQ:SYBX) to $9 from $22 after the company discontinued development of SYNB1020, an early-stage clinical product candidate for the treatment of hyperammonemia. The stock...

August 20, 2019

Markets

Brookline starts SCYNEXIS at buy; PT $5

Brookline Capital Markets launched coverage of SCYNEXIS (NASDAQ:SCYX) with a “buy” rating and $5 price target. The stock closed at $1.07 on Aug. 19. Analyst Kumaraguru Raja writes that SCYNEXIS’ lead product candidate...

August 20, 2019

Markets

Analysts start Castle Biosciences at buy and OP with PTs of $25-to-$28

Analysts for SVB Leerink, BTIG and Canaccord Genuity launched coverage of Castle Biosciences (NASDAQ:CSTL), saying the company answers a large unmet need in skin cancer. The stock closed at $20.25 on Aug. 16. SVB...

August 19, 2019

Markets

HCW starts Entasis Therapeutics at buy; PT $18

H.C. Wainwright initiated coverage of Entasis Therapeutics (NASDAQ:ETTX) with a “buy” rating and $18 price target. The stock closed at $8.25 on Aug. 16. Spun out of AstraZeneca in 2015, Entasis is focused on novel...

August 19, 2019

Markets

HCW cuts Trillium Therapeutics to neutral and removes PT

H.C. Wainwright downgraded Trillium Therapeutics (NASDAQ:TRIL) to “neutral” from “buy” and removed its price target, saying the precipitous fall in the stock price could lead to a cash crunch. Over the last six months...

August 19, 2019

Markets

SVB Leerink starts Myovant Sciences at OP; PT $26

SVB Leerink initiated coverage of Myovant Sciences (NYSE:MYOV) with an “outperform” rating and $26 price target. The stock closed at $7 on Aug. 16. “Myovant’s lead product, relugolix, is poised to become the second...

August 19, 2019

Markets

Dawson James starts BeyondSpring at buy; PT $39

Dawson James Securities initiated coverage of BeyondSpring (NASDAQ:BYSI) with a “buy” rating and price target of $39. The stock closed at $16.21 on Aug. 15. “BeyondSpring’s [flagship molecule] Plinabulin is well...

August 16, 2019

Markets

Brookline starts Vaxart at buy; PT $6

Brookline Capital Markets launched coverage of Vaxart (NASDAQ:VXRT) with a “buy’ rating and $6 price target. The stock closed at 66 cents on Aug. 14. Vaxart is focused on oral, recombinant vaccines that are expected to...

August 15, 2019

Subscribe